中证智能财讯 启明医疗-B（02500）4月29日披露2024年度报告。报告期内，公司实现营业总收入5.09亿元，同比下降30.51%；归母净利润亏损7.14亿元，上 年同期亏损7.04亿元；经营活动产生的现金流量净额为2373.9万元，上年同期为-6.1亿元；据报告显示，启明医疗-B基本每股收益为-1.63元，加权平均净资 产收益率为-27.5%。 以4月29日收盘价计算，启明医疗-B目前市净率（TTM）约0.47倍，市销率（TTM）约2.23倍。 市净率(LF)历史分位(%) 001 900 93d3 80-78 80 70 63-94 60 50 2012 44:22 40 3745 30 20 10 11606 0 2019-12-37 1 1-12-37 J-12-37 2n- 制图数据来自恒生聚源数据库 100 + 93:51- 83:41 % 50 58-54 32.19 0 -23:31 -30.51 -50 -100 -150 -200 2022 2023 2019 2020 2021 2024 -○- 营业总收入同比增长率 -○- 归母净利润同比增长率 制图数据来自恒生聚源数据库 总营收、 ...

2024 年度報告 | 公司資料 | 2 | | --- | --- | | 董事長致辭 | 4 | | 財務摘要 | 6 | | 董事會報告 | 62 | | 企業管治報告 | 94 | | 釋 義 | 257 | 2024年度報告 2 目錄 | 6 | 財務摘要 | | --- | --- | | 7 | 管理層討論與分析 | | 52 | 董事、監事及高級管理層 | | 62 | 董事會報告 | | 94 | 企業管治報告 | | 126 | 獨立核數師報告 | | 131 | 綜合損益及其他全面收益表 | | 133 | 綜合財務狀況表 | | 135 | 綜合權益變動表 | | 136 | 綜合現金流量表 | | 139 | 綜合財務報表附註 | 公司資料 | 中文名稱： | 杭州啓明醫療器械股份有限公司 | | --- | --- | | 英文名稱： | Venus Medtech（Hangzhou）Inc. | | 法定代表： | 林浩昇先生 | | 董事長： | 胡定旭先生 | | 註冊資本： | 人民幣441,011,443元 | | 中國總部： | | | 註冊及辦事處地址 | 中國杭州濱 ...

金十期货4月29日讯，伦敦金属交易所（LME）有色金属库存及变化如下： 1. 铜库存202500吨，减少300吨。 2. 铝库存417575吨，减少2000吨。 3. 镍库存201564吨，增加138吨。 4. 锌库存177550吨，减少1775吨。 5. 铅库存267275吨，减少3750吨。 6. 锡库存2665吨，减少180吨。 LME有色金属库存日报 ...

智通财经APP讯，启明医疗-B(02500)发布截至2024年12月31日止年度业绩，该集团期内取得收益人民币 4.71亿元。 公告称，于报告期内，公司持续聚焦结构性心脏病领域，通过优化研发管线布局，进一步提升研发效 率，集中资源推进核心重点管线的临床进展。全球临床研发项目取得多项重要里程碑，展现公司强大的 全球临床研发及运营实力，国际化进程不断深化。公司自主研发首款自膨干瓣TAVR产品Venus- PowerX、首款球扩干瓣TAVR产品Venus-Vitae和肺动脉瓣膜产品VenusP-Valve相继开展临床试验，临床 进展稳步推进中;三尖瓣置换产品Cardiovalve欧洲关键性临床研究患者入组进展顺利，即刻术后效果优 异，展现出优秀的安全性和有效性，深受海外专家医生好评。这些产品未来有望为全球患者提供更加优 质的治疗方案。 截至本公告日期，公司已成功建立由十款创新器械组成的产品管线，涵盖心脏瓣膜疾病领域。心脏瓣膜 类疾病介入治疗是集团布局的核心治疗领域。公司产品包括已商业化四款TAVR产品–VenusA-Valve， VenusA-Plus，VenusA-Pro和VenusA-Deluxe，一款TPVR ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （於中華人民共和國註冊成立的股份有限公司） （股份代號：2500） 截至二零二四年十二月三十一日止年度之 年度業績公告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」或「集 團」）截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度（「報告期」）之 經 審 核 綜 合 業 績，連 同 二 零 二 三 年 同 期 之 比 較 數 字。 財務概要 | | 截至二零二四年 | 截至二零二三年 | | | --- | --- | --- | --- | | | 十二月三十一日 | 十二月三十一日 | | | | 止 ...

消息面上，近日，由启明医疗自主研发的自膨胀式经导管肺动脉瓣膜产品VenusP-Valve在澳大利亚 墨尔本权威医院The Royal Melbourne Hospital成功开展澳大利亚首例商业应用。公司表示，VenusP- Valve在这重要的市场实现了首例商业化植入，标志着这款全球首个且唯一在中国和欧洲获批上市的自 膨胀式肺动脉瓣膜产品已正式推开澳洲市场的大门。 启明医疗-B大涨超22% VenusP-Valve在澳大利亚成 功开展首例商业化植入 启明医疗-B(02500)大涨超22%，截至发稿，涨22.4%，报2.24港元，成交额3184.42万港元。 据悉，启明医疗的瓣膜业务仍展现出强劲韧性。在国内市场，公司在心脏瓣膜行业维持龙头地位， 产品不断取得创新突破：全球首款应用于经导管主动脉瓣置换术(TAVR)的全释放全回收干瓣系统Venus- PowerX已于2024年12月在华西医院完成注册临床研究的全球首例入组，该确证性临床试验的启动标志 着其向临床转化迈出关键一步，有望在今年完成全部患者的临床入组，成为公司的下一个增长点。 ...

급 启明医疗 VENUSMEDTECH 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. (於中華人民共和國註冊成立的股份有限公司) 股份代號：2500 2024 中期報告 ® | --- | --- | --- | --- | --- | |-------|-------|-------|-------|----------------------------------| | | | | | | | | | | | | | | | | | 目錄 | | | | 2 | | 公司資料 | | | | 4 | | 財務摘要 | | | | 5 | | 管理層討論與分析 | | | | 28 | | 企業管治及其他資料 | | | | 49 | | 簡明綜合財務報表審閱報告 | | | | 51 | | 中期簡明綜合損益及其他全面收益表 | | | | 53 | | 中期簡明綜合財務狀況表 | | | | 55 | | 中期簡明綜合權益變動表 | | | | 57 | | 中期簡明綜合現金流量表 | | | | 60 | | 中期簡明綜合財務資料附註 | | | | | ...

B_table indent_4.5 mm N_table indent_4 mm 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 財務概要 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二四年六月三十日止六個月之 中期業績公告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 之未經審核綜合中期業績，連同二零二三年同期之比較數字。 | --- | --- | --- | --- | |---------------------------------------------- ...

Corporate Governance and Management Changes - The company appointed Lin Haosheng as the new General Manager effective November 20, 2023[4]. - The company has undergone significant changes in its board, with Hu Dingxu appointed as Chairman following the resignation of previous Chairman Zeng Min[4]. - The company has experienced changes in its board of directors, with several key resignations and appointments throughout 2023, including the resignation of the chairman and general manager[109][113]. - The board currently consists of seven directors, including three executive directors, two non-executive directors, and two independent non-executive directors, which does not meet the minimum requirements set by the listing rules[114]. - The company has established three board committees: the Audit Committee, the Remuneration and Assessment Committee, and the Nomination Committee[192]. - The company has a clear profit distribution plan and loss compensation strategy as part of its operational governance[184]. - The company has a structured approach to corporate governance, adhering to the corporate governance code and relevant regulations[194]. - The company is actively seeking suitable candidates to fill the vacancies of independent non-executive directors to comply with listing rules[114]. Financial Performance and Revenue Growth - Total revenue for the fiscal year ended December 31, 2023, reached RMB 491.37 million, an increase from RMB 406.46 million in 2022, representing a growth of approximately 20.9%[7]. - The company's total revenue for the year ended December 31, 2023, was RMB 491.4 million, an increase of 20.9% compared to RMB 406.5 million for the year ended December 31, 2022[32]. - Sales from the VenusA series products accounted for 83.4% of total revenue, while VenusP-Valve contributed 15.6% for the year ended December 31, 2023[33]. - The company's gross profit increased by 23.9% to RMB 389.2 million for the year ended December 31, 2023, compared to RMB 314.0 million for the previous year[35]. - The gross margin improved from 77.2% for the year ended December 31, 2022, to 79.2% for the year ended December 31, 2023, primarily due to economies of scale in production[35]. - Other income and gains for the year ended December 31, 2023, amounted to RMB 241.6 million, an increase of 63.2% compared to RMB 148.0 million for the year ended December 31, 2022, primarily due to fair value adjustments related to the acquisition agreement with Nuocheng[36]. Product Development and Market Expansion - The company is focusing on expanding its market presence and enhancing its product offerings[2]. - The company is committed to developing new technologies and products to strengthen its competitive position in the market[2]. - The company aims to deepen its international market expansion and enhance its commercialization pipeline through innovative product development[10]. - The company has established a product pipeline consisting of 12 innovative devices targeting heart valve diseases, hypertrophic cardiomyopathy, and hypertension[11]. - VenusP-Valve has entered over 50 countries and regions, including Germany, France, the UK, Italy, Spain, Australia, and Canada, with ongoing international expansion efforts[6]. - The company is actively pursuing strategic initiatives, including potential mergers and acquisitions, to drive growth[2]. - The company is focusing on expanding its product pipeline and enhancing its market position with innovative technologies and clinical trials[14][15][17][18]. Clinical Trials and Research - The company is advancing the Cardiovalve Target CE clinical trial for tricuspid valve replacement, with over 70 patients enrolled across more than 20 renowned centers in Europe and North America[6]. - The Venus-Vitae and Venus-PowerX products are in the critical clinical trial phase, with early feasibility studies completed in Argentina and Chile[12]. - The Liwen RF system for treating hypertrophic cardiomyopathy has completed patient enrollment for critical clinical studies[12]. - Cardiovalve's clinical trial for TMVR/TTVR products is progressing rapidly, with over 70 patients enrolled in the TARGET CE pivotal trial across more than 20 medical centers in the UK, Germany, Italy, and Canada[20]. - The Liwen RF radiofrequency ablation system achieved a treatment success rate of 86.1% (68/79) in a follow-up of 79 patients six months post-surgery, significantly improving key clinical endpoints[21]. Financial Challenges and Losses - The company reported a pre-tax loss of RMB 735.34 million for 2023, an improvement from a loss of RMB 1,156.34 million in 2022[7]. - The basic and diluted loss per share for 2023 was RMB 1.61, compared to RMB 2.42 in 2022, reflecting a reduction in losses[7]. - The company has faced cumulative losses since its establishment and anticipates potential future losses due to the high-risk nature of the medical device industry[71]. - Future growth is heavily dependent on the successful development and commercialization of its pipeline products, with significant risks associated with clinical trials and regulatory approvals[71]. Regulatory Compliance and Risk Management - The company is required to conduct a special audit and forensic investigation regarding loans provided to certain individuals and disclose the findings[62]. - Regulatory compliance is critical, as delays in obtaining necessary approvals could severely impact the commercialization of pipeline products[73]. - The company recognizes that risk management is crucial for business success, facing operational risks related to the medical device market and regulatory changes in China and globally[81]. - The audit committee oversees the overall risk management related to business operations, including reviewing and approving risk management policies and monitoring significant risks[82]. - The company has adopted a comprehensive risk management policy to identify, assess, and monitor key risks related to strategic objectives on a continuous basis[83]. Shareholder and Ownership Structure - As of December 31, 2023, the total issued share capital of the company is 441,011,443 shares, consisting of 441,010,235 H shares and 1,208 non-listed foreign shares[134]. - Major shareholder Mr. Zeng holds 33,651,618 H shares, representing 7.63% of the total issued share capital[136]. - The company has a diverse shareholder base, with multiple entities holding significant stakes, including Qiming Venture Partners III, L.P. with 40,018,283 H shares, or 9.07%[137]. - The total percentage of H shares held by major shareholders indicates a concentrated ownership structure, with the top three shareholders holding over 27% of the total shares[136][137]. Corporate Social Responsibility and Environmental Compliance - The company emphasizes sustainable and environmentally friendly practices, aiming to minimize its carbon footprint[103]. - The company has complied with all relevant environmental laws and regulations during the reporting period[103]. - The group reported charitable donations amounting to RMB 42.8 million during the reporting period, a decrease from RMB 70.3 million in the previous year[149]. Marketing and Sales Strategies - The company utilizes a strategic marketing model to promote its products through partnerships with hospitals and leveraging its opinion leader network for academic marketing in China[105]. - The company actively participates in significant cardiology conferences in China, showcasing product innovations and providing training on TAVR and TPVR procedures[106]. - The marketing efforts primarily target large tertiary hospitals, which have more resources for interventional cardiac valve procedures compared to smaller hospitals[106]. - The company relies on opinion leaders to introduce and recommend its products to physicians and hospitals, enhancing clinical benefits through academic incentives[106].

B_table indent_4.5 mm N_table indent_4 mm 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全 部 或 任 何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 截至二零二三年十二月三十一日止年度之 年度業績公 告 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至 二 零 二 三 年 十 二 月 三 十 一 日 止 年 度（「報告期」）之未經審核 綜合業績，連同二零二二年同期 之 比較數字。 財務概要 | --- | --- | --- | --- | |----------------------|------------ ...